pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›tobevibart
drug · antibody
save

tobevibart

Phase 3updated 6mo ago
by $VIR Vir Biotechnology, Inc.🔗 ChEMBL
Phase 3
community read0 votes

Antibody drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying tobevibart

  • phase3A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infectionactive not recruitingn=124
  • phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtiderecruitingn=150
  • phase2A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infectionactive not recruitingn=100

News(8)

  • Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
    Vir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.
    biospace · 7d ago
  • Vir hepatitis D drug succeeds in first pivotal study
    A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
    biopharma_dive · 7d ago
  • Vir’s phase 3 hepatitis delta win fuels push to eclipse Gilead
    Vir Biotechnology’s phase 3 trial in chronic hepatitis delta has hit its primary endpoint, giving the biotech the first piece of the package it needs to file for FDA approval next year.
    fiercebiotech · 8d ago
  • Vir says hepatitis D drug combination succeeds in first pivotal study
    Vir Biotechnology’s chronic hepatitis D treatment has succeeded in the first of three late-stage studies, stoking competition with Gilead and Mirum Pharmaceuticals. Vir said Sunday afternoon that 4…
    endpoints · 8d ago
  • GSK, Ionis hepatitis B functional cure breaks open market for followers
    The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.
    biospace · 25d ago
  • Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers
    The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tu…
    biospace · 1mo ago
  • Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
    Looking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.
    fiercebiotech · 1mo ago
  • Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
    A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead S…
    fiercebiotech · 1mo ago
generic
tobevibart
indication
Hepatitis D
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?